Publication

Skoulidis F, Ahn MJ, Gadgeel S, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC (Krascendo 1). N Engl J Med, 2026

PMID 42929675

Open-label phase 3 RCT (Roche), 338 patients with previously treated KRAS G12C-mutated advanced NSCLC. Divarasib vs sotorasib/adagrasib: median PFS 9.8 vs 5.7 months (HR 0.58; 95% CI 0.44-0.76); median OS 17.7 vs 12.0 months (HR 0.56; 95% CI 0.41-0.78); grade 3-4 treatment-related AEs 24.6% vs 34.5%.

News about this publication

Also in the catalogue

Scales

Identifiers

PMID
42929675
DOI
10.1056/NEJMoa2605703

Original sources

Details

Journal
N Engl J Med
Year
2026

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.